van der Bijl A E, Teng Y K O, van Oosterhout M, Breedveld F C, Allaart C F, Huizinga T W J
Leiden University Medical Centre, Leiden, The Netherlands.
Arthritis Rheum. 2009 Jul 15;61(7):974-8. doi: 10.1002/art.24513.
To evaluate the efficacy and safety of intraarticular infliximab compared with intraarticular methylprednisolone in patients with gonarthritis.
In 23 patients with recurrent gonarthritis despite previous intraarticular corticosteroid therapy, a total of 41 intraarticular injections (20 infliximab and 21 methylprednisolone) were performed in 28 knees. Initial therapy was randomly assigned, and crossover therapy was eligible within 3 months. The clinical effect was assessed during 6 months of followup. The primary outcome was event-free survival, defined as the time after treatment until local retreatment was performed and/or nonimprovement of the knee joint score. Adverse effects were recorded during followup.
All patients treated with intraarticular infliximab had an insufficient response. In contrast, 8 of the 21 intraarticular methylprednisolone injections were effective (P = 0.004). Between groups, no differences in the patients' age, disease duration, number of disease-modifying antirheumatic drugs, or previous intraarticular methylprednisolone were observed. Reported adverse effects were not related to therapy.
Treatment with intraarticular infliximab injection was not effective in patients with a chronically inflamed knee joint. Intraarticular injection with methylprednisolone was superior despite previous intraarticular corticosteroid therapy. Further investigation is needed to provide these patients with a better alternative.
评估关节腔内注射英夫利昔单抗与关节腔内注射甲泼尼龙治疗膝关节炎患者的疗效和安全性。
对23例尽管先前接受过关节腔内皮质类固醇治疗但仍复发膝关节炎的患者,在28个膝关节中总共进行了41次关节腔内注射(20次英夫利昔单抗和21次甲泼尼龙)。初始治疗随机分配,3个月内 eligible进行交叉治疗。在6个月的随访期间评估临床效果。主要结局是无事件生存期,定义为治疗后至进行局部再次治疗和/或膝关节评分未改善的时间。随访期间记录不良反应。
所有接受关节腔内英夫利昔单抗治疗的患者反应不足。相比之下,21次关节腔内注射甲泼尼龙中有8次有效(P = 0.004)。两组之间,在患者年龄、病程、改善病情抗风湿药数量或先前关节腔内甲泼尼龙使用情况方面未观察到差异。报告的不良反应与治疗无关。
关节腔内注射英夫利昔单抗对慢性炎症膝关节患者无效。尽管先前接受过关节腔内皮质类固醇治疗,但关节腔内注射甲泼尼龙效果更佳。需要进一步研究为这些患者提供更好的替代方案。